Biodesix (BDSX) to Release Earnings on Monday

Biodesix (NASDAQ:BDSX) is expected to release its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect Biodesix to post earnings of ($1.1298) per share and revenue of $23.1220 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.56. Biodesix had a negative return on equity of 1,760.83% and a negative net margin of 39.85%.The company had revenue of $28.76 million during the quarter, compared to analyst estimates of $26.25 million. On average, analysts expect Biodesix to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Biodesix Trading Up 0.9%

NASDAQ:BDSX opened at $11.08 on Friday. Biodesix has a 12 month low of $3.44 and a 12 month high of $20.21. The stock has a 50 day moving average of $14.39 and a two-hundred day moving average of $10.34. The firm has a market cap of $112.02 million, a P/E ratio of -2.28 and a beta of 0.43.

Insider Activity

In other news, CEO Scott Hutton sold 3,559 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the completion of the sale, the chief executive officer directly owned 45,413 shares in the company, valued at $457,763.04. This represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 9,052 shares of company stock valued at $100,227 in the last ninety days. 23.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biodesix

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd grew its position in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares in the last quarter. Cetera Investment Advisers acquired a new position in Biodesix in the fourth quarter valued at approximately $68,000. DRW Securities LLC acquired a new position in Biodesix in the fourth quarter valued at approximately $105,000. Millennium Management LLC acquired a new position in Biodesix in the third quarter valued at approximately $113,000. Finally, State Street Corp lifted its holdings in Biodesix by 15.6% in the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after acquiring an additional 2,400 shares during the last quarter. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BDSX. William Blair upgraded Biodesix from a “market perform” rating to an “outperform” rating in a research note on Friday, February 27th. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Biodesix in a research report on Tuesday, February 17th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.